Literature DB >> 29306989

Kynurenine is correlated with IL-1β in plasma of schizophrenia patients.

Helena P G Joaquim1,2, Alana C Costa1,2, Wagner F Gattaz1,2, Leda Leme Talib3,4.   

Abstract

The etiology of schizophrenia is still unclear. It is well-known that pro-inflammatory cytokines are higher in schizophrenia patients since the first episode psychosis comparing to healthy controls. Inflammatory downstream cascades influence different cellular pathways, like the displacement of the tryptophan (TRP) metabolism to the production of kynurenine (KYN) instead of serotonin, which results in the generation of several neuro and immunoactive metabolites. The aim of this study was to determine TRP, KYN and IL-1β plasma levels in first-onset schizophrenia (n = 28) and healthy controls (n = 30). The plasmatic levels of TRP and KYN were decreased in schizophrenic patients (p = 0.004 and p = 0.002, respectively), but there was no difference in the ratio of KYN/TRP (p = 0.554) or either in IL-1β (p = 0.101). Positive correlation was observed between KYN and IL-1β only in the schizophrenia group (r = 0.461, p = 0.021). And, there was also positive correlation between KYN and Positive and Negative Symptoms Scale (PANSS) (r = 0.395, p = 0.037). There is no correlation between the other analytes and other parameters of PANSS. Although our results of KYN have been different than expected and there was no difference in the KYN/TRP ratio, we observed a positive correlation between IL-1β and KYN, corroborating findings that pro-inflammatory agents hold up the KYN pathway.

Entities:  

Keywords:  IL-1β; Kynurenine; Schizophrenia; Tryptophan

Mesh:

Substances:

Year:  2018        PMID: 29306989     DOI: 10.1007/s00702-018-1838-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  43 in total

1.  Diagnosis of functional psychoses: time to face the future.

Authors:  Michael J Owen; Nick Craddock
Journal:  Lancet       Date:  2009-01-17       Impact factor: 79.321

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

3.  Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.

Authors:  A M Myint; M J Schwarz; R Verkerk; H H Mueller; J Zach; S Scharpé; H W M Steinbusch; B E Leonard; Y K Kim
Journal:  Brain Behav Immun       Date:  2011-05-17       Impact factor: 7.217

4.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

5.  The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines.

Authors:  Hidetsugu Fujigaki; Kuniaki Saito; Suwako Fujigaki; Masao Takemura; Kaori Sudo; Hiroshi Ishiguro; Mitsuru Seishima
Journal:  J Biochem       Date:  2006-04       Impact factor: 3.387

Review 6.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

7.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

Review 8.  L-kynurenine: its synthesis and possible regulatory function in brain.

Authors:  E M Gál; A D Sherman
Journal:  Neurochem Res       Date:  1980-03       Impact factor: 3.996

Review 9.  Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease--there is no schizoaffective disorder.

Authors:  Charles Ray Lake; Nathaniel Hurwitz
Journal:  Curr Opin Psychiatry       Date:  2007-07       Impact factor: 4.741

10.  Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia.

Authors:  Francesco Fazio; Luana Lionetto; Martina Curto; Luisa Iacovelli; Michele Cavallari; Cristina Zappulla; Martina Ulivieri; Flavia Napoletano; Matilde Capi; Valentina Corigliano; Sergio Scaccianoce; Alessandra Caruso; Jessica Miele; Antonio De Fusco; Luisa Di Menna; Anna Comparelli; Antonella De Carolis; Roberto Gradini; Robert Nisticò; Antonio De Blasi; Paolo Girardi; Valeria Bruno; Giuseppe Battaglia; Ferdinando Nicoletti; Maurizio Simmaco
Journal:  Sci Rep       Date:  2015-12-08       Impact factor: 4.379

View more
  9 in total

1.  Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.

Authors:  Joshua Chiappelli; Francesca M Notarangelo; Ana Pocivavsek; Marian A R Thomas; Laura M Rowland; Robert Schwarcz; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2018-02-27       Impact factor: 7.853

2.  The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.

Authors:  Abbas F Almulla; Asara Vasupanrajit; Chavit Tunvirachaisakul; Hussein K Al-Hakeim; Marco Solmi; Robert Verkerk; Michael Maes
Journal:  Mol Psychiatry       Date:  2022-04-14       Impact factor: 15.992

3.  Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia.

Authors:  Yan Zhang; Han Shi; Ge Yang; Yongfeng Yang; Wenqiang Li; Meng Song; Minglong Shao; Xi Su; Luxian Lv
Journal:  Transl Psychiatry       Date:  2021-11-20       Impact factor: 6.222

4.  Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.

Authors:  Ping Lin; Junyu Sun; Xiaoyan Lou; Dan Li; Yun Shi; Zhenhua Li; Peijun Ma; Ping Li; Shuzi Chen; Weifeng Jin; Shuai Liu; Qing Chen; Qiong Gao; Lili Zhu; Jie Xu; Mengyuan Zhu; Mengxia Wang; Kangyi Liang; Ling Zhao; Huabin Xu; Ke Dong; Qingtian Li; Xunjia Cheng; Jinghong Chen; Xiaokui Guo
Journal:  Gen Psychiatr       Date:  2022-02-23

Review 5.  Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis.

Authors:  Connor Dunleavy; Richard J Elsworthy; Rachel Upthegrove; Stephen J Wood; Sarah Aldred
Journal:  Acta Psychiatr Scand       Date:  2022-03-05       Impact factor: 7.734

6.  Tryptophan Challenge in Healthy Controls and People with Schizophrenia: Acute Effects on Plasma Levels of Kynurenine, Kynurenic Acid and 5-Hydroxyindoleacetic Acid.

Authors:  Korrapati V Sathyasaikumar; Francesca M Notarangelo; Deanna L Kelly; Laura M Rowland; Stephanie M Hare; Shuo Chen; Chen Mo; Robert W Buchanan; Robert Schwarcz
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-15

7.  Inflammatory Pathways in Psychiatric Disorders: The case of Schizophrenia and Depression.

Authors:  Tami Feng; Ashutosh Tripathi; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2020-07-26

8.  Peripheral Biomarkers for First-Episode Psychosis-Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia.

Authors:  Nuno Trovão; Joana Prata; Orlando VonDoellinger; Susana Santos; Mário Barbosa; Rui Coelho
Journal:  Psychiatry Investig       Date:  2019-03-07       Impact factor: 2.505

9.  Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease.

Authors:  Madis Parksepp; Liisa Leppik; Kadri Koch; Kärt Uppin; Raul Kangro; Liina Haring; Eero Vasar; Mihkel Zilmer
Journal:  Sci Rep       Date:  2020-08-19       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.